Pharmacyclics begins phase-one trials

Article

Pharmacyclics has received clearance from the Food and Drug Administrationto begin phase-one clinical trials to investigate the safety andutility of its gadolinium-texaphyrin agent for MRI contrast andradiation therapy applications.

Pharmacyclics has received clearance from the Food and Drug Administrationto begin phase-one clinical trials to investigate the safety andutility of its gadolinium-texaphyrin agent for MRI contrast andradiation therapy applications.

Gadolinium-texaphyrin is an expanded porphyrin compound thatdiffers from current extracellular contrast media in that it hasbeen shown to enter cancer cells selectively, according to theSunnyvale, CA, company.

Gadolinium-texaphyrin is the second Pharmacyclics MRI agentto enter human clinical studies and the first agent based on thecompany's texaphyrin technology. Another Pharmacyclics agent,Gadolite, is well into phase-three clinical studies, the companysaid.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.